HLN
Haleon Plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.28
−0.85%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$9.20
From 52W high−17.66%
Volume45.17M
Market cap$40.81B
P/E (TTM)19.3x
P/S (TTM)2.8x
Div yield2.10%
Key dataSep 18, 2026
Open
$9.20
From 52W high
−17.66%
Volume
45.17M
Market cap
$40.81B
ValuationView details →
P/E (Fwd)
20.6x
EV/EBITDA
13.2x
P/E (TTM)
19.3x
RSI (14)
37.4
MomentumView details →
1D Return
−0.85%
YTD Return
−8.65%
SummaryUpdated Jun 1, 2026
Haleon plc (LSE:HLN) is a British multinational consumer healthcare company that was spun off from GlaxoSmithKline in July 2022, making it one of the world's largest standalone consumer healthcare companies. The company was formed through the demerger of GSK's consumer healthcare division, which had been built over decades through acquisitions and internal development. Headquartered in Brentford, United Kingdom, Haleon operates globally across North America, Europe, Middle East, Africa, Latin America, and Asia Pacific, managing a portfolio of well-established consumer health brands that reach millions of consumers daily.
Similar companies
Latest newsMore news →
Haleon reported growing US sales of products targeting side-effects of weight-loss drugs, capitalizing on rising popularity of GLP-1 medications.4d agoHaleon secured improved shelf placement agreements with U.S. retailers Walmart and Target to increase product visibility and market share.17d agoHaleon's antacid brand ENO launched a new advertising campaign in India, 'Acidity ke kayi naam, ENO sab par kare kaam', to educate consumers about acidity-related symptoms.35d ago